Excitingly, combination treatment with anti-LAG-3 and anti-PD-1 antibodies in mice resistant to treatment with single antibodies showed a strong anti-tumor effect in the absence of obvious evidence of autoimmunity, suggesting the possibility of clinical efficacy and safety through combination treatment with anti-LAG-3 and anti-PD-1 antibodies [36]. The gene discussed is LAG3; the disease is neoplasm.